Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
Keyword(s):
AbstractA randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.
2020 ◽
Vol 59
(12)
◽
pp. 1330-1341
◽
2018 ◽
Vol 3
(3)
◽
pp. 40
◽
2003 ◽
Vol 143
(1)
◽
pp. 16-25
◽
2015 ◽
Vol 30
(3)
◽
pp. 253-262
◽